Bicara Therapeutics Inc. 8-K Filing
Ticker: BCAX · Form: 8-K · Filed: Dec 8, 2025 · CIK: 2023658
| Field | Detail |
|---|---|
| Company | Bicara Therapeutics Inc. (BCAX) |
| Form Type | 8-K |
| Filed Date | Dec 8, 2025 |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Bicara Therapeutics Inc. (ticker: BCAX) to the SEC on Dec 8, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (nge on which registered Common Stock, $0.0001 par value BCAX The Nasdaq Global Market).
How long is this filing?
Bicara Therapeutics Inc.'s 8-K filing is 3 pages with approximately 854 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 854 words · 3 min read · ~3 pages · Grade level 12.2 · Accepted 2025-12-08 07:11:43
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value BCAX The Nasdaq Global Market
Filing Documents
- bcax-20251206.htm (8-K) — 30KB
- esmoasia2025presentation.htm (EX-99.1) — 13KB
- bicaraesmoasia2025clinic.htm (EX-99.2) — 28KB
- bicaraesmoasia2025clinic001.jpg (GRAPHIC) — 74KB
- bicaraesmoasia2025clinic002.jpg (GRAPHIC) — 305KB
- bicaraesmoasia2025clinic003.jpg (GRAPHIC) — 90KB
- bicaraesmoasia2025clinic004.jpg (GRAPHIC) — 82KB
- bicaraesmoasia2025clinic005.jpg (GRAPHIC) — 124KB
- bicaraesmoasia2025clinic006.jpg (GRAPHIC) — 124KB
- bicaraesmoasia2025clinic007.jpg (GRAPHIC) — 125KB
- bicaraesmoasia2025clinic008.jpg (GRAPHIC) — 100KB
- bicaraesmoasia2025clinic009.jpg (GRAPHIC) — 126KB
- bicaraesmoasia2025clinic010.jpg (GRAPHIC) — 105KB
- bicaraesmoasia2025clinic011.jpg (GRAPHIC) — 88KB
- bicaraesmoasia2025clinic012.jpg (GRAPHIC) — 48KB
- bicaraesmoasia2025clinic013.jpg (GRAPHIC) — 104KB
- bicaraesmoasia2025clinic014.jpg (GRAPHIC) — 136KB
- bicaraesmoasia2025clinic015.jpg (GRAPHIC) — 132KB
- bicaraesmoasia2025clinic016.jpg (GRAPHIC) — 114KB
- bicaraesmoasia2025clinic017.jpg (GRAPHIC) — 36KB
- bicaraesmoasia2025clinic018.jpg (GRAPHIC) — 109KB
- bicaraesmoasia2025clinic019.jpg (GRAPHIC) — 113KB
- bicaraesmoasia2025clinic020.jpg (GRAPHIC) — 95KB
- bicaraesmoasia2025clinic021.jpg (GRAPHIC) — 109KB
- bicaraesmoasia2025clinic022.jpg (GRAPHIC) — 47KB
- esmoasia2025presentation001.jpg (GRAPHIC) — 227KB
- esmoasia2025presentation002.jpg (GRAPHIC) — 258KB
- esmoasia2025presentation003.jpg (GRAPHIC) — 273KB
- esmoasia2025presentation004.jpg (GRAPHIC) — 64KB
- 0002023658-25-000112.txt ( ) — 4631KB
- bcax-20251206.xsd (EX-101.SCH) — 2KB
- bcax-20251206_lab.xml (EX-101.LAB) — 23KB
- bcax-20251206_pre.xml (EX-101.PRE) — 13KB
- bcax-20251206_htm.xml (XML) — 3KB
01 - Regulation FD Disclosure
Item 7.01 - Regulation FD Disclosure. On December 6, 2025, Bicara Therapeutics Inc. (the "Company") issued a press release titled "Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026" in connection with an oral presentation at the European Society for Medical Oncology Asia Congress ("ESMO Asia"). A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Also on December 6, 2025, the Company hosted a clinical update webcast. A copy of the clinical update presentation is available in the investor relations section of the Company's website at https://ir.bicara.com/ and is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information set forth under Item 7.01, including Exhibits 99.1 and 99.2, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item8.01 – Other Events. On December 6, 2025, the Company announced preliminary data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizumab in first-line human papillomavirus-negative recurrent/metastatic ("R/M") head and neck squamous cell carcinoma ("HNSCC"). Phase 1/1b expansion cohort data presented at ESMO Asia show that 750mg ficerafusp alfa in combination with pembrolizumab was generally well-tolerated, with a safety profile consistent with the known safety profile of ficerafusp alfa plus pembrolizumab in R/M HNSCC. At a preliminary duration of follow-up, 750mg of ficerafusp alfa demonstrated a 57% (17/
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits (d) The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release, dated December 6, 2025, furnished hereto. 99.2 Clinical Update Presentation, furnished hereto. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 8th day of December, 2025. Bicara Therapeutics Inc. By: /s/ Claire Mazumdar Name: Claire Mazumdar, Ph.D. Title: Chief Executive Officer